Fiona Lampe

Summary

Affiliation: University of Zurich
Country: Switzerland

Publications

  1. ncbi Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
    B Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University of Zurich, Switzerland
    Lancet 353:863-8. 1999
  2. ncbi Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups
    B Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    N Engl J Med 344:168-74. 2001
  3. ncbi Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
    Bruno Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Lancet 364:51-62. 2004
  4. ncbi Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study
    Bruno Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    Clin Infect Dis 45:111-9. 2007
  5. doi Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study
    Nina Khanna
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Basel, Basel, Switzerland
    Clin Infect Dis 48:1459-66. 2009
  6. ncbi Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study
    Catia Marzolini
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Antivir Ther 15:413-23. 2010
  7. doi Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals
    Luigia Elzi
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    HIV Clin Trials 10:207-14. 2009
  8. ncbi Morbidity and mortality in HIV-infected individuals - a shift towards comorbidities
    Manuel Battegay
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Swiss Med Wkly 139:564-70. 2009
  9. ncbi Comprehensive clinical adherence interventions to enable antiretroviral therapy: a case report
    Dunja Nicca
    Division of Clinical Nursing Science, University Hospital, Basel, Switzerland
    J Assoc Nurses AIDS Care 18:44-53. 2007
  10. ncbi Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study
    Luigia Elzi
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    AIDS 20:129-31. 2006

Collaborators

Detail Information

Publications12

  1. ncbi Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
    B Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University of Zurich, Switzerland
    Lancet 353:863-8. 1999
    ..The efficacy of highly active antiretroviral therapy (HAART) in suppression of HIV-1 is well documented. We investigated virological and clinical outcomes of HAART in routine practice...
  2. ncbi Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups
    B Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    N Engl J Med 344:168-74. 2001
    ..Whether secondary prophylaxis against P. carinii pneumonia can be safely discontinued in patients who have a response to highly active antiretroviral therapy is not known...
  3. ncbi Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
    Bruno Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Lancet 364:51-62. 2004
    ..We aimed to assess the inter-relations between viral load, CD4-cell count, and clinical outcome in patients who had experienced three-class virological failure...
  4. ncbi Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study
    Bruno Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    Clin Infect Dis 45:111-9. 2007
    ..Human immunodeficiency virus (HIV)-infected persons may be at increased risk for developing type 2 diabetes mellitus because of viral coinfection and adverse effects of treatment...
  5. doi Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study
    Nina Khanna
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Basel, Basel, Switzerland
    Clin Infect Dis 48:1459-66. 2009
    ..We investigated the incidence and outcome of progressive multifocal leukoencephalopathy (PML) in human immunodeficiency virus (HIV)-infected individuals before and after the introduction of combination antiretroviral therapy (cART) in 1996...
  6. ncbi Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study
    Catia Marzolini
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Antivir Ther 15:413-23. 2010
    ..We investigated the prevalence of comedications and PDDIs within a large HIV cohort, and their effect on ART efficacy and tolerability...
  7. doi Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals
    Luigia Elzi
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    HIV Clin Trials 10:207-14. 2009
    ..We aimed to evaluate the efficacy and the impact of discontinuing and/or switching enfuvirtide on virologic and clinical parameters in clinical practice...
  8. ncbi Morbidity and mortality in HIV-infected individuals - a shift towards comorbidities
    Manuel Battegay
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Swiss Med Wkly 139:564-70. 2009
    ..The changing pattern of HIV-associated diseases may indicate the need for specific preventive measures in this population...
  9. ncbi Comprehensive clinical adherence interventions to enable antiretroviral therapy: a case report
    Dunja Nicca
    Division of Clinical Nursing Science, University Hospital, Basel, Switzerland
    J Assoc Nurses AIDS Care 18:44-53. 2007
    ....
  10. ncbi Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study
    Luigia Elzi
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    AIDS 20:129-31. 2006
    ..Pharmacokinetic data indicated therapeutic concentrations for both protease inhibitors in most patients...
  11. ncbi Antiretroviral therapy of late presenters with advanced HIV disease
    Manuel Battegay
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    J Antimicrob Chemother 62:41-4. 2008
    ..We encourage physicians to perform HIV testing more frequently in order to detect HIV-infected individuals in time...
  12. ncbi Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir
    Urs Karrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Switzerland
    AIDS 19:1987-94. 2005
    ..This effect might be related to ddI toxicity since ddI exposure is substantially increased by TDF...